via pharmatimes.com
There was some bad news for Boehringer Ingelheim's Spiriva after the mist inhaler formulation, which is co-marketed by Pfizer for chronic obstructive pulmonary disease, was linked with a 52% increase in the risk of death.
There was some bad news for Boehringer Ingelheim's Spiriva after the mist inhaler formulation, which is co-marketed by Pfizer for chronic obstructive pulmonary disease, was linked with a 52% increase in the risk of death.
No comments:
Post a Comment